DongKook Life Science Co., Ltd.

DongKook Life Science Co., Ltd.

KKRX:303810
1,654.00
KRW
-56.00
(-3.27%)
159.88EPS
15.45P/E
79.00BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
30,144.72
40,629.1
44,047.64
48,950.28
3,209.97
3,352.74
5,363.9
2,348.9
4,139.92
3,784
Basic EPS, GAAP
2,112.5
2,772
2,804.5
1,990
183.14
132.55
186
40
275
159.88
Free Cash Flow per Basic Share
2,979.2
1,870.61
471.79
-6,796.92
-940.7
-634.54
-419.53
115.02
-166.97
39.03
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1,153.23
1,320.64
1,567.63
1,702.43
1,890.58
2,036.3
2,148.08
3,289.89
4,107.21
4,149
Tangible Book Value per Share
1,145.65
1,314.38
1,565
1,680.17
1,710.07
1,849.82
1,962.51
3,109.42
3,944.37
4,005.02
Basic Weighted Avg Shares
2
2
2
2
32
32
22
56
31
31
Sales/Revenue/Turnover
50,450
87,707
98,617
109,583
102,668
107,234
120,161
131,816
130,344
117,747
Operating Margin (%)
7.49
8.15
7.05
7.69
6.62
5.81
7.1
9.04
10.01
8.65
Depreciation Expense
467
1,343
2,014
2,089
2,385
2,461
3,283
5,782
6,411
6,580
Net Income, GAAP
3,535
5,984
6,279
4,455
5,858
4,239
4,167
2,245
8,658
4,975
Effective Tax Rate (%)
- -
23.78
14.67
33.72
8.94
19.72
13.73
52.77
20.04
20.92
Profit Margin (%)
7.01
6.82
6.37
4.07
5.71
3.95
3.47
1.7
6.64
4.23
Working Capital
30,477
35,021
36,064
21,402
2,618
10,024
11,514
52,776
57,888
57,914
LT Debt
360
120
64
89
10,205
25,237
18,788
22,509
5,424
5,296
Total Equity
36,885
42,240
50,139
54,451
60,469
65,129
68,704
105,224
131,366
132,702
Return on Invested Capital (%)
- -
11.66
11.48
9.75
8.77
5.33
6.7
4.26
6.55
4.86
Return on Capital (%)
- -
13.32
12.57
9.37
11.28
7.49
7.59
4.51
7.28
4.32
Return on Common Equity (%)
- -
15.13
13.59
8.52
10.19
6.75
6.23
2.58
7.32
3.82

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
33,559
33,765
32,498
LT Borrowings
3,687
3,588
3,488
LT Finance Leases
1,737
1,922
1,807
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
32
32
32
Market Capitalization
117,062
108,746
79,001

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
138,560
144,389
137,304
Cash, Cash Equivalents & STI
7,254
8,182
8,323
Accounts Receivable, Net
90,658
97,057
95,413
Inventories
35,230
33,516
27,988
Total Current Liabilities
80,672
84,514
79,389
Payables & Accruals
- -
- -
- -
ST Debt
33,559
33,765
32,498
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
20.45%
24.84%
Free Cash Flow
- -
-67.73%
-181.45%
Net Income, GAAP
- -
48.35%
285.71%
Sales/Revenue/Turnover
- -
3.75%
-1.12%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
33,567
34,044
32,410
31,795
131,816
2025
35,050
34,889
29,438
30,967
130,344
2026
33,084
24,258
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
30.5
-29
67
-24.5
40
2025
37.5
44.5
75.39
39.8
275
2026
72.09
-28
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Jae-Won Park
Full Time Employees
203
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Teheran-ro 108-gil 7 Seoul SL South Korea
IPO Date
Feb 17, 2025
Website
dkls.co.kr
Business
DongKook Life Science Co., Ltd. is a specialized pharmaceutical company engaged in the development, manufacturing, and sale of diagnostic pharmaceutical products and medical devices. The company's core offerings include contrast media for diagnostic imaging such as X-ray contrast media, nuclear magnetic resonance (MRI) contrast media, iodized oil contrast media, and related diagnostic pharmaceutical products. It also manufactures and distributes active pharmaceutical ingredients (APIs) including Cilastatin Sodium, Gadobutrol, Iopamidol, DOTA, and others, alongside medical and diagnostic equipment. DongKook Life Science operates globally, supplying its products to 17 countries. Founded in 2017 and headquartered in Seoul, South Korea, DongKook Life Science applies advanced technologies in desalting, purification, and sterilization to ensure high-quality and innovative products for the diagnostic medicine market. The company targets healthcare providers and diagnostic centers worldwide. Recent major developments include the company’s successful ₩18 billion (approximately USD 12.5 million) initial public offering (IPO) on the Korea Exchange in 2025, marking it as South Korea's first med-tech listing of the year. Furthermore, DongKook Life Science signed a strategic partnership memorandum of understanding (MOU) with China's Zhejiang Tianyu to enhance its market presence and collaborate on product development and distribution. These moves reflect the company’s strategic expansion and commitment to strengthening its global footprint in the diagnostic pharmaceutical and medical device sectors.